Stefanie Mason
Vice President, Head of Clinical Development Rivus Pharmaceuticals
Seminars
Wednesday 16th September 2026
Panel Discussion: Balancing Differentiation, Combination Strategies & Commercial Reality to Define the Next Generation of Successful MASH Therapies
4:10 pm
- Evaluating how developers can differentiate new therapies within an increasingly competitive landscape to demonstrate meaningful clinical value, enabling stronger positioning and improving future adoption
- Assessing when combination approaches are likely to provide the greatest therapeutic advantage over monotherapy strategies, improving development prioritization and maximizing long-term patient benefit
- Defining the clinical, regulatory and commercial attributes required for future therapies to succeed beyond initial approval, strengthening development decision-making and supporting long-term market impact
Thursday 17th September 2026
Leveraging an Energy Expenditure Mechanism to Drive Liver-Targeted Reductions in Fat and Inflammation, the Primary Drivers of MASH
10:00 am
- Leveraging a mitochondrial uncoupling approach to increase resting energy expenditure, resulting in muscle-preserving reductions in fat, particularly visceral fat, while independently reducing inflammation.
- Utilizing a liver-targeted therapy to reduce liver fat and inflammation, the primary drivers of MASH, while preserving muscle, which is critical for sustained cardiometabolic health.
- Developing oral small molecule therapies with favorable tolerability profiles to address chronic metabolic dysfunction, improving long-term patient management, and supporting sustained cardiometabolic health.
